Image
Funding for multinational clinical trials

Calls

Funding opportunities for investigators

At ECRIN we can provide support to investigators for the preparation of calls for multinational clinical trial funding, provided that the projects are funded and meet the ECRIN eligibility criteria.

For more information on how ECRIN can support you in the preparation of these calls, see Clinical Trials Preparation and contact your local European Correspondent.

The calls listed below may be relevant for your applications for clinical trials / clinical research in various fields. In the News section of our website, you can also find additional information on calls on diverse topics other than clinical trials.

ECRIN Discover marker Discover the European funding programs for multinational clinical trials.

Call Launch :

Description :

The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.

ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.

The Anticancer Fund announces the launch of a call for research projects in the treatment of rare cancers, together with five other organisations. It is the second time this consortium, ATTRACT, funds clinical trials to stimulate the development of better treatments for rare cancer patients.

ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition (ATTRACT 2023), we are excited to organise a second call for projects in September 2024. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.

Call Launch :

Deadline :

Deadline 2 :

Description :

Call for Proposals for Multinational and Translational Research Projects on Bidirectional Brain-Body Interactions

Maintenance, improvement, and restoration of human brain health are of fundamental importance and a worldwide priority. It has become increasingly evident that bidirectional communication between the central nervous system and the body has significant implications for maintaining both homeostatic and brain function. Abnormalities in brain–body interaction linked to genetic, environmental or lifestyle factors encompass a wide range of conditions affecting millions worldwide. Dysregulation of the brain-body axis can potentially contribute to or exacerbate various neurological and psychiatric disorders. The estimated prevalence can vary significantly depending on factors such as geographic location, population demographics, and advancements in medical diagnosis.

The study of bidirectional interactions between the central nervous system and the body is an emerging field of research that holds the potential to enhance our understanding of often overlooked pathophysiological processes involved in common neurological and psychiatric disorders. Expanding our current knowledge in this area is crucial as it serves as the initial step towards the development of therapeutic and preventive approaches aimed at preserving and improving brain health on a global scale.

The 'Network of European Funding for Neuroscience Research' (NEURON) has been established under the ERA-NET scheme of the European Commission (www.neuron-eranet.eu). The ERA-NET NEURON aims to coordinate and optimize research efforts and funding programmes of its partner countries/regions in the field of mental, neurological, and sensory disorders. Under the umbrella of NEURON, a joint transnational call (JTC 2024) in the field of bidirectional brain-body interactions will be launched in 2024.

Call Launch :

Description :

LifeArc announces £5 million drug repurposing programme for motor neuron disease

 

  • LifeArc is launching new £5m programme to help find new treatments for motor neuron disease (MND).
  • The programme is seeking applications from the international MND research community for research projects looking at repurposed drugs and drug combinations to tackle the neurodegenerative condition.
  • The programme will verify the potential effectiveness of promising treatments to improve their chance of success in clinical trials in unique offering in fight against MND.
  • Funding is part of LifeArc’s multi-million pound Motor Neuron Disease Translational Challenge to make MND treatable by 2030 and ultimately find a cure.
  • MND is a neurodegenerative condition that affects the brain and nerves causing weakness, loss of movement and is currently fatal.

 

LifeArc announced today that it will commit £5 million in grant funding to find new treatments for motor neuron disease (MND) as part of a drug repurposing programme to tackle the high failure rate in MND clinical trials.

Currently, potential treatments for MND, including repurposed drugs, have failed to show beneficial effects in patients and the failure rate for treatments in clinical trials for MND remains very high. LifeArc aims to improve the success rate of clinical trials by funding pre-clinical research studies on repurposed drugs that show potential and, uniquely, verify that they could be effective in treating MND.

International research teams in academia and small and medium-sized enterprises (SMEs) are eligible to take part in the programme, with funding of up to £750,000 per project available. To be considered eligible for funding, applicants must have identified a new repurposed drug with experimental evidence that shows it has potential for treating MND.

The chosen projects will benefit from LifeArc’s deep expertise, advice and mentorship in translational research, its drug-repurposing know-how and access to its collaborative network of project partners. This is all part of the charity’s aim to support the next generation of translational scientists and give projects the best chance of success.

This funding call is part of LifeArc’s Motor Neuron Disease Translational Challenge to make the condition treatable by 2030 and ultimately find a cure. Breaking the research deadlock in MND is a key priority for the charity and forms part of the Challenge’s £50 million investment to accelerate the translation of scientific discoveries into new breakthroughs to transform how MND is detected, treated, and managed.

Currently, around half of those diagnosed with MND die within two years and six people are diagnosed with MND every day in the UK. The condition currently affects around 5,000 people in the UK and more than 330,000 worldwide. There are currently no treatments that can cure the condition and the only licensed drug for MND in the UK has a modest effect on extending life.

Dr Paul Wright, Head of LifeArc’s MND Translational Challenge, said: “We are fortunate to have exceptional research in the MND community both in the UK and further afield but despite this, most clinical trials using repurposed drugs fail due to lack of effectiveness. Improving confidence in drug repurposing requires more robust preclinical research, meaning that repurposed drug candidates are progressed into trials with sufficient evidence to predict they could benefit someone living with MND. To achieve our ambition of making MND treatable by 2030, we need to start with better decision making at the pre-clinical stage to demonstrate as early as possible that a repurposed drug candidate has the potential to deliver improvements for patients.”

David Setters, MND campaigner and co-founder of Patients United to End MND, said: “This major initiative gives the MND community another boost as we build on recent exciting progress in research. While the development of new therapies remains crucial, the key benefit of repurposing is a shorter trial timescale given that the drugs will have already passed safety tests. The increased prospect of access to more trials in the relatively near future not only brings hope to patients, but also a heightened sense of “self-worth” by being involved in research. Those of us living with this brutal condition greatly appreciate the considerable funding and impetus that LifeArc has brought to MND research in recent years. The team’s focus on translational research to accelerate the arrival of meaningful treatments combined with a desire to harness emerging discoveries from around the world, as with this new programme, gives us a real lift.”

Dr Jane Haley MBE, Director of Research at MND Scotland, added: “Motor neuron disease is rapid, brutal and terminal, and people with MND don’t have time to wait, so it is important that all avenues to possible new treatments are explored. Repurposing of existing licenced medicines is one way of speeding up the process of finding effective treatments. It’s been tried very successfully in cancer, where it has delivered many new treatments for patients, so it is important that MND researchers learn from their successes. We welcome LifeArc’s £5 million investment in this area – it is about time there was a world without MND, and this can only be achieved through research.”

Dr Brian Dickie MBE, Director of Research Development at the MND Association, said: “This exciting new funding call will provide a real shot in the arm for the research community, catalysing the translation of the vast new knowledge gained about MND in recent years and feeding the pipeline of repurposed drug candidates available for clinical trials.”

Jessica Lee, Director of Research at My Name’5 Doddie Foundation, said: “MND research is at a tipping point; we have never known more about the biology underpinning MND and our research community is collaborating like never before. We now need urgent and coordinated investment to drive forward the search for new treatments. We are pleased to welcome LifeArc’s new funding call which could bring new treatments to people living with MND in years, not decades, and we look forward to supporting the programme in any way we can.”

The funding call will be underpinned by the Guiding principles for drug discovery and development in amyotrophic lateral sclerosis white paper that is also being published today. This is the output of a year-long project that has brought together leading researchers, clinicians, industry experts and people living with MND to outline an agreed approach to reduce the risk of clinical trials of new treatments through an enhanced evidenced-based approach to pre-clinical research.

Researchers interested in applying for funding are encouraged to join a webinar about the project taking place in February 2024 and can register here.

A parallel funding scheme to support data science and AI/machine learning approaches to repurposed drug candidate identification in MND will also be made available through the programme. LifeArc will fund up to five bioinformatic projects that aim to exploit MND data sets with up to £100,000 available per project over 12 months.

Call Launch :

Deadline :

Description :

*Please note the dates for call launch and deadlines are not official yet. We will modify them as soon as this information is available.

IHI published draft information on future call topics a few months ahead of the official call launch. The aim is to give you additional time to find or build a consortium and prepare a strong proposal.

Note that as draft topics are still under development, the texts may change considerably between the versions published here and the call launch, and you should always check the final, approved topic texts once the calls are launched.

Topics:

  • Improving clinical management of heart disease from early detection to treatment
  • User-centric technologies and optimised hospital workflows for a sustainable healthcare workforce
  • Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response

The topics are currently under consultation with the States’ Representatives Group (SRG) and the Science and Innovation Panel (SIP). They may therefore change considerably between the versions published here and the call launch, and applicants should check the final, approved topic texts once the calls are launched.

Call Launch :

Deadline :

Description :

*Please note the dates for call launch and deadlines are not official yet. We will modify them as soon as this information is available.

IHI published draft information on future call topics a few months ahead of the official call launch. The aim is to give you additional time to find or build a consortium and prepare a strong proposal.

Note that as draft topics are still under development, the texts may change considerably between the versions published here and the call launch, and you should always check the final, approved topic texts once the calls are launched.

Topics:

  • Support healthcare system resilience through a focus on persistency in the treatment of chronic diseases
  • Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-making

The topics are currently under consultation with the States’ Representatives Group (SRG) and the Science and Innovation Panel (SIP). They may therefore change considerably between the versions published here and the call launch, and applicants should check the final, approved topic texts once the calls are launched.